Vectus Biosystems (ASX:VBS) EV-to-EBIT

: -9.49 (As of Today)

View and export this data going back to 2016. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Vectus Biosystems's Enterprise Value is A$28.14 Mil. Vectus Biosystems's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 was A$-2.97 Mil. Therefore, Vectus Biosystems's EV-to-EBIT for today is -9.49.

The historical rank and industry rank for Vectus Biosystems's EV-to-EBIT or its related term are showing as below:

ASX:VBS' s EV-to-EBIT Range Over the Past 10 Years
Min: -22.1 Med: 0 Max: 0
Current: -9.49

ASX:VBS's EV-to-EBIT is ranked worse than
100% of 542 companies
in the Biotechnology industry
Industry Median: 1.94 vs ASX:VBS: -9.49

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Vectus Biosystems's Enterprise Value for the quarter that ended in Dec. 2022 was A$35.27 Mil. Vectus Biosystems's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 was A$-2.97 Mil. Vectus Biosystems's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2022 was -8.41%.

Vectus Biosystems EV-to-EBIT Historical Data

The historical data trend for Vectus Biosystems's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

EV-to-EBIT

-5.19

-4.16

-8.09

-11.99

-12.26

Vectus Biosystems Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22
EV-to-EBIT										-	-11.99	-	-12.26	-

Competitive Comparison

For the Biotechnology subindustry, Vectus Biosystems's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Vectus Biosystems EV-to-EBIT Distribution

For the Biotechnology industry and Healthcare sector, Vectus Biosystems's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Vectus Biosystems's EV-to-EBIT falls in comparison to its industry or sector. The grey bar indicates the EV-to-EBIT's extreme value range as defined by GuruFocus.

Vectus Biosystems EV-to-EBIT Calculation

Vectus Biosystems's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	28.138	/	-2.965
	=	-9.49

Vectus Biosystems's current Enterprise Value is A$28.14 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vectus Biosystems's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 was A$-2.97 Mil.

Vectus Biosystems (ASX:VBS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Vectus Biosystems's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2022 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2022 )	=	EBIT	/	Enterprise Value (Q: Dec. 2022 )
	=	-2.965	/	35.272335
	=	-8.41 %

Vectus Biosystems's Enterprise Value for the quarter that ended in Dec. 2022 was A$35.27 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vectus Biosystems's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 was A$-2.97 Mil.

Vectus Biosystems EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Vectus Biosystems (ASX:VBS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018

Website

http://www.vectusbiosystems.com.au

Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems (ASX:VBS) Headlines

No Headlines